MedTrace Logo

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

NCT04337463 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-05-17

No results posted yet for this study

Summary

This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ATG-008

Tablet

DRUG

Toripalimab

IV infusion

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Li Zheng · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2022-05-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337463 on ClinicalTrials.gov